




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01K 67/027, C07K 14/16, C12N 7/04, 7/01, A61K 39/008, 39/21, C12N 1/10, 1/36, G06T 7/00		A3	(11) International Publication Number: WO 98/44788
			(43) International Publication Date: 15 October 1998 (15.10.98)
(21) International Application Number: PCT/US98/06944		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 9 April 1998 (09.04.98)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(30) Priority Data: 08/838,702 9 April 1997 (09.04.97) US 08/848,760 1 May 1997 (01.05.97) US 60/069,163 9 December 1997 (09.12.97) US		(88) Date of publication of the international search report: 11 March 1999 (11.03.99)	
(71)(72) Applicant and Inventor: CHANG, Lung-Ji [-/US]; 3102 N.W. 57th Terrace, Gainesville, FL 32606-6939 (US).			
(74) Agents: PACE, Doran, R. et al.; Saliwanchik, Lloyd & Saliwanchik, Suite A-1, 2421 NW 41st Street, Gainesville, FL 32606-6669 (US).			

(54) Title: ANIMAL MODEL FOR EVALUATION OF VACCINES



(57) Abstract

The present invention provides animals and methods for the evaluation of vaccines. In particular, the present invention provides humanized animal models for the evaluation of vaccines designed to confer immunity against human pathogens, including vaccines directed against the human immunodeficiency virus. The present invention further relates to HIV vaccines. In particular, the present invention provides attenuated replication-competent HIV vaccines and replication-defective HIV vaccines. In addition, the invention provides modified *Leishmania* cells expressing HIV proteins.